Atlab, BZL Biologics join forces to develop Lu-J591 for cancer treatment
The agreement comprises exclusive rights to manufacture, develop and commercialize the drug candidate across the globe, besides a joint Phase IIB/III clinical validation program. In addition, Atlab Pharma
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.